Cargando…
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
PURPOSE: This study aims to determine the incidence of nausea and vomiting (CINV) after moderately emetogenic chemotherapy (MEC), under medical practice conditions and the accuracy with which physicians perceive CINV. METHODS: Chemotherapy-naive patients receiving MEC between April 2012 and May 2013...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519584/ https://www.ncbi.nlm.nih.gov/pubmed/26081597 http://dx.doi.org/10.1007/s00520-015-2809-3 |
_version_ | 1782383518335107072 |
---|---|
author | Escobar, Yolanda Cajaraville, Gerardo Virizuela, Juan Antonio Álvarez, Rosa Muñoz, Andrés Olariaga, Olatz Tamés, María José Muros, Begoña Lecumberri, María Jose Feliu, Jaime Martínez, Purificación Adansa, Juan Carlos Martínez, María José López, Rafael Blasco, Ana Gascón, Pere Calvo, Virginia Luna, Pablo Montalar, Joaquín Del Barrio, Patricia Tornamira, María Victoria |
author_facet | Escobar, Yolanda Cajaraville, Gerardo Virizuela, Juan Antonio Álvarez, Rosa Muñoz, Andrés Olariaga, Olatz Tamés, María José Muros, Begoña Lecumberri, María Jose Feliu, Jaime Martínez, Purificación Adansa, Juan Carlos Martínez, María José López, Rafael Blasco, Ana Gascón, Pere Calvo, Virginia Luna, Pablo Montalar, Joaquín Del Barrio, Patricia Tornamira, María Victoria |
author_sort | Escobar, Yolanda |
collection | PubMed |
description | PURPOSE: This study aims to determine the incidence of nausea and vomiting (CINV) after moderately emetogenic chemotherapy (MEC), under medical practice conditions and the accuracy with which physicians perceive CINV. METHODS: Chemotherapy-naive patients receiving MEC between April 2012 and May 2013 were included. Patients completed a diary of the intensity of nausea and number of vomiting episodes. Complete response and complete protection were assessed as secondary endpoints. RESULTS: Of 261 patients included, 240 were evaluated. Median age was 64 years, 44.2 % were female and 11.2 % were aged less than 50 years; 95.3 % of patients received a combination of 5-hydroxytryptamine 3 (5-HT(3)) antagonist + corticosteroid as antiemetic treatment. Vomiting within 5 days of chemotherapy administration occurred in 20.8 %, nausea in 42 % and significant nausea in 23.8 % of patients. An increase in the percentage of patients with significant nausea (from 9.4 to 21.7 %) and vomiting (from 9.2 to 16.5 %) was observed from the acute to the delayed phase. Complete response was 84.2 % in the acute phase, 77 % in the late phase and 68.9 % in overall period. Complete protection was 79.5 % in the acute phase, 68.8 % in the late phase and 62.4 % throughout the study period. Physicians estimated prophylaxis would be effective for 75 % of patients receiving MEC, compared with 54.1 % obtained from patients’ diary. CONCLUSION: Despite receiving prophylactic treatment, 31 % of patients did not achieve a complete response and 38 % complete protection. In general, nausea was worse controlled than vomiting. The results also showed the late phase was worse controlled than the acute phase in all variables. Healthcare providers overestimated the effectiveness of antiemetic prophylaxis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00520-015-2809-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4519584 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-45195842015-08-03 Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study Escobar, Yolanda Cajaraville, Gerardo Virizuela, Juan Antonio Álvarez, Rosa Muñoz, Andrés Olariaga, Olatz Tamés, María José Muros, Begoña Lecumberri, María Jose Feliu, Jaime Martínez, Purificación Adansa, Juan Carlos Martínez, María José López, Rafael Blasco, Ana Gascón, Pere Calvo, Virginia Luna, Pablo Montalar, Joaquín Del Barrio, Patricia Tornamira, María Victoria Support Care Cancer Original Article PURPOSE: This study aims to determine the incidence of nausea and vomiting (CINV) after moderately emetogenic chemotherapy (MEC), under medical practice conditions and the accuracy with which physicians perceive CINV. METHODS: Chemotherapy-naive patients receiving MEC between April 2012 and May 2013 were included. Patients completed a diary of the intensity of nausea and number of vomiting episodes. Complete response and complete protection were assessed as secondary endpoints. RESULTS: Of 261 patients included, 240 were evaluated. Median age was 64 years, 44.2 % were female and 11.2 % were aged less than 50 years; 95.3 % of patients received a combination of 5-hydroxytryptamine 3 (5-HT(3)) antagonist + corticosteroid as antiemetic treatment. Vomiting within 5 days of chemotherapy administration occurred in 20.8 %, nausea in 42 % and significant nausea in 23.8 % of patients. An increase in the percentage of patients with significant nausea (from 9.4 to 21.7 %) and vomiting (from 9.2 to 16.5 %) was observed from the acute to the delayed phase. Complete response was 84.2 % in the acute phase, 77 % in the late phase and 68.9 % in overall period. Complete protection was 79.5 % in the acute phase, 68.8 % in the late phase and 62.4 % throughout the study period. Physicians estimated prophylaxis would be effective for 75 % of patients receiving MEC, compared with 54.1 % obtained from patients’ diary. CONCLUSION: Despite receiving prophylactic treatment, 31 % of patients did not achieve a complete response and 38 % complete protection. In general, nausea was worse controlled than vomiting. The results also showed the late phase was worse controlled than the acute phase in all variables. Healthcare providers overestimated the effectiveness of antiemetic prophylaxis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00520-015-2809-3) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2015-06-17 2015 /pmc/articles/PMC4519584/ /pubmed/26081597 http://dx.doi.org/10.1007/s00520-015-2809-3 Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Escobar, Yolanda Cajaraville, Gerardo Virizuela, Juan Antonio Álvarez, Rosa Muñoz, Andrés Olariaga, Olatz Tamés, María José Muros, Begoña Lecumberri, María Jose Feliu, Jaime Martínez, Purificación Adansa, Juan Carlos Martínez, María José López, Rafael Blasco, Ana Gascón, Pere Calvo, Virginia Luna, Pablo Montalar, Joaquín Del Barrio, Patricia Tornamira, María Victoria Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study |
title | Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study |
title_full | Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study |
title_fullStr | Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study |
title_full_unstemmed | Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study |
title_short | Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study |
title_sort | incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: advice (actual data of vomiting incidence by chemotherapy evaluation) study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519584/ https://www.ncbi.nlm.nih.gov/pubmed/26081597 http://dx.doi.org/10.1007/s00520-015-2809-3 |
work_keys_str_mv | AT escobaryolanda incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy AT cajaravillegerardo incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy AT virizuelajuanantonio incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy AT alvarezrosa incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy AT munozandres incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy AT olariagaolatz incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy AT tamesmariajose incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy AT murosbegona incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy AT lecumberrimariajose incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy AT feliujaime incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy AT martinezpurificacion incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy AT adansajuancarlos incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy AT martinezmariajose incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy AT lopezrafael incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy AT blascoana incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy AT gasconpere incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy AT calvovirginia incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy AT lunapablo incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy AT montalarjoaquin incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy AT delbarriopatricia incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy AT tornamiramariavictoria incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy |